London (ots/PRNewswire) – Bryan, Garnier Co, the pan-European investment bank for growth companies, announces the successful $275 million Nasdaq IPO for Galapagos NV, a major European clinical-stage biotechnology company. Bryan, Garnier Co is the only European investment bank in the IPO syndicate. The Galapagos IPO on Nasdaq confirms the strong momentum of the European healthcare sector.

(Logo: )

Galapagos NV announced today the pricing of its global offering totaling $275 million gross proceeds, initially filed for $150 million. The new shares were placed in a concurrent public offering in the US through ADSs at a price of $42.05 and private placement in Europe at a price of EUR37 per share. It is the largest Nasdaq IPO of a European biotech and one of three largest biotech IPO ever in Europe or in the US.

Bryan, Garnier Co acted as co-manager and sole European investment bank, alongside Morgan Stanley, Credit Suisse, Cowen and Company and Nomura.

Bryan Garnier Co keeps on leading the financing of the European healthcare companies, in Europe and in the US:

- Bryan, Garnier  Co was the only European investment bank involved in the
  top 5 IPOs of European healthcare companies on Nasdaq i.e. Galapagos (Belgium), DBV
  Technology (France), Forward Pharma (Denmark), Cellectis (France), Adaptimune (UK), as
  well as in the IPO of LDR Holding (US/France).
- Bryan, Garnier  Co confirms its leading position in the financing of the
  European emerging biopharma industry, through private equity placements, PIPEs, and
  public offerings, on both the European and the American equity capital markets (LSE,
  AIM, Euronext, Alternext, and Nasdaq OMX).
- Cumulated placements managed by Bryan, Garnier  Co in healthcare exceeded
  1bEUR over the past 24 months including 3 Nasdaq IPOs (Galapagos, DBV Technologies and
  LDR Holding).

For more information, please contact Anna Emelianenko ( | +33-1-56-68-75-00) or Daiana Hirte ( | +33-1-56-26-72-00).

About Galapagos:

About Bryan, Garnier Co:



Kommentare sind geschlossen.